Abstract:
Objective:To study the prognostic significance of cell proliferation and apoptosis, MVD and clinicopathologi -cal parameters for the recurrence of synovial sarcoma. Methods:We analyzed the clinical and follow-up data of56synovial sarcoma patients without metastasis. RT-PCR was used to detect the subtype of SYT-SSX fusion gene. The expression of Ki 67and MVD was detected by immunohistochemistry. Univariate analysis was employed to analyze the influence of the above factors and clinicopathological parameters on the recurrence free survival and to explore the influencing factors for the recurrence of synovial sarcoma. Results: Of all the patients,73.2% (41/56) had recurrence during the follow-up. The median recurrence free survival was19.5 months. The recurrence free 1-, 2-, 3-, 4-, and 5-year survival rates after surgery were45.0%,41.0%,34.0%,28.0%, and28.0%, respectively. Ki-67labeling index (LI) was 19.98%±11.64% and MVD was 51.83± 21.92per ×400 . There was no significant difference in apoptotic index (AI) between the two groups ( P=0.607 ). χ2 analysis showed that histological type (P=0.000 ) and MVD ( P=0.045 ) were significantly correlated with the recurrence of sy-novial sarcoma. Univariate analysis showed that Ki 67 LI ( P=0.009 ), histological type ( P=0.012 ) and radiotherapy ( P=0.014 ) were significantly correlated with the recurrence free survival of synovial sarcoma patients. Sex ( P=0.015 ), tumor lo -cation ( P=0.411 ), tumor size ( P=0.801 ), necrosis ( P=0.486 ), MVD (P=0.454 ), chemotherapy ( P=0.272 ), and apoptotic grade (P=0.899 ) were not correlated with the recurrence free survival of synovial sarcoma patients. Multivariate analysis re -vealed that higher expression of Ki 67(RR= 1.944 , P=0.045 ), radiotherapy (RR=0.482 , P=0.04), and histological type (RR=0.207 , P=0.031 ) were independent risk factors for the recurrence of synovial sarcoma. Conclusion:The expression of Ki67, radiotherapy and histological type are important factors for evaluating the recurrence and prognosis of synovial sarcoma.